AIM ImmunoTech Inc. — Director's Dealing 2016

Mar 21, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2016-03-18

Reporting Person: Equels Thomas K. (Director, CEO,Pres,Exec Vice Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-18	Common Stock	P	30000	$0.1322	Acquired	1484548	Direct